News

The cystic fibrosis (CF) community will get a firsthand look at the anticipated findings of the Wave 1 multi-dose trial conducted by the Gene Therapy Consortium (GTC), which includes the University of Oxford’s Gene Medicine Group, the University of Edinburgh’s Centre for Molecular Medicine and Roslin Institute, and Imperial College…

An international research team led by researchers at the Sapienza University of Rome in Italy reported that the assessment of daily physical activity in adult patients with cystic fibrosis (CF) could be used as a valuable tool to determine their aerobic fitness and exercise performance. The study was published in…

During the American Thoracic Society 2015 International Conference being held in Denver, Colorado, 15-20 of May, researchers from Oregon State University, Corvallis (OSU), and Aradigm Corporation will present a study entitled “Treatment of Mycobacterium Avium Subsp Hominissuis (MAH) Lung Infections with Liposome-Encapsulated Ciprofloxacin Resulted in Significant Decrease in Bacterial Load in the…

After the Pulmonary-Allergy Drugs Advisory Committee (PADAC) met to discuss the approval of Orkambi, members of the committee voted 12 to 1 recommending Vertex Pharmaceuticals’ new treatment for cystic fibrosis to be approved by the US Food and Drug Administration for marketing. The indication is for cystic…

Results from a recent study conducted by a team of researchers from the University of Pennsylvania’s Perelman School of Medicine indicate that only half of women with a diagnosis of cystic fibrosis (CF) use contraceptives and often opt for unplanned pregnancies. The study findings were presented last week during the…

Organ donors are critical to the survival of patients whose organs experience severe damage through trauma and disease. However, on average twenty-one people die per day while waiting for a transplant. As a disease that features lung transplantation as a possible course of treatment, those in the cystic fibrosis patient…

The Food and Drug Administration (FDA) will be evaluating the new drug application (NDA) for Vertex Pharmaceutical’s Orkambi, indicated to treat cystic fibrosis in patients with the F508del mutation on Tuesday, and will make a final decision for approval/disapproval by July 5. The Pulmonary-Allergy Drugs Advisory Committee (PADAC) will be…

CARSTAR Automotive Canada Inc. is encouraging Canadians to promote CARSTAR’s Great Strides™ Walk for Cystic Fibrosis Canada through the social media hashtag #AWorldWithoutCF throughout the month of May. The goal is to raise funds to support research and treatments to address cystic fibrosis (CF). CARSTAR is celebrating its first…

Spyryx Biosciences, Inc. has successfully raised $18 million in Series A venture capital financing, which will be used to develop novel therapies to treat respiratory conditions such as cystic fibrosis (CF) and chronic obstructive pulmonary disease (COPD). The funding was secured through deals with Canaan Partners, Hatteras Venture Partners and…

Parion Sciences, a biopharmaceutical company developing treatments to improve and extend the lives of patients with innate mucosal surface defense deficiencies of the eye or lungs, recently announced that it has begun enrollment of patients with Cystic Fibrosis (CF) in a phase 2 clinical trial of its experimental therapy…